.jpg?format=webp&width=780)
Results from the prospective, multicentre FIRE trial, in which irreversible electroporation (IRE) was assessed as a salvage therapy for patients with radio-recurrent focal prostate cancer. The treatment was safe and showed minimal toxicity. In addition, after 12 months, 93% of patients preserved continence, and 73% did not show any local or systemic disease. Thus, IRE provided encouraging oncological outcomes and might be a much-needed potential alternative therapy for patients with localized prostate cancer who had not experienced any benefit from radiotherapy.
Like
Save
Share